Vanguard Global Advisers’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Vanguard Global Advisers's RAPP Position: Q3 2026 in Review
Vanguard Global Advisers increased its Rapport Therapeutics (RAPP) stake by 16% in Q3 2026, buying an estimated $123K and bringing the position to 20,079 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #1943.
Vanguard Global Advisers first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $718K in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Vanguard Global Advisers held 20,079 shares of Rapport Therapeutics worth $675K as of Q3 2026.
- Vanguard Global Advisers bought 2,839 Rapport Therapeutics shares in Q3 2026, an estimated $123K.
- Rapport Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1943 holding.
- Vanguard Global Advisers first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Rapport Therapeutics position peaked at $718K in Q2 2026.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.